Lei Qian

Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight

Mazdutide versus placebo in Chinese adults with type 2 diabetes

Efficacy and safety of Tafolecimab in Chinese patients with type 2 diabetes and hypercholesterolemia: a post-hoc analysis of pooled data from three phase 3 trials

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes

Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China

Efficacy and Safety of Efdamrofusp Alfa versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4)

Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial

Collaborative Research: Conference: NAIRR Pilot Expansion: FA1: Mid-South Conferences on CyberInfrastructure Advances to Enable Interdisciplinary AI Research in Health

Beginnings: Creating and Sustaining a Diverse Community of Expertise in Quantum Information Science (EQUIS) Across the Southeastern United States